Jazz Pharmaceuticals (FRA:J7Z) Debt-to-Equity : 1.55 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Debt-to-Equity?

Jazz Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €573 Mil. Jazz Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €4,738 Mil. Jazz Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €3,427 Mil. Jazz Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 1.55.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Jazz Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

FRA:J7Z' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.57 Med: 0.86 Max: 1.88
Current: 1.55

During the past 13 years, the highest Debt-to-Equity Ratio of Jazz Pharmaceuticals was 1.88. The lowest was 0.57. And the median was 0.86.

FRA:J7Z's Debt-to-Equity is ranked worse than
92.72% of 1071 companies
in the Biotechnology industry
Industry Median: 0.15 vs FRA:J7Z: 1.55

Jazz Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Jazz Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Debt-to-Equity Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.57

0.62

1.55

1.88

1.55

Jazz Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.88	1.74	1.65	1.66	1.55

Competitive Comparison of Jazz Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Jazz Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jazz Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Debt-to-Equity falls into.

Jazz Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Jazz Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(572.576	+	4738.334)	/	3426.826
	=	1.55

Jazz Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(572.576	+	4738.334)	/	3426.826
	=	1.55

Jazz Pharmaceuticals (FRA:J7Z) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Jazz Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals (FRA:J7Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

JAZZ:USA JAZZ:Mexico

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (FRA:J7Z) Headlines

No Headlines